Marinus Pharmaceuticals

$16.10
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.04 (-0.25%) As of 8:37 PM UTC today

Why Robinhood?

You can buy or sell MRNS and other stocks, options, and ETFs commission-free!

About MRNS

Marinus Pharmaceuticals, Inc. Common Stock, also called Marinus Pharmaceuticals, is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw on August 14, 2003 and is headquartered in Radnor, PA. The listed name for MRNS is Marinus Pharmaceuticals, Inc. Common Stock.

CEO
Scott N. Braunstein
Employees
40
Headquarters
Radnor, Pennsylvania
Founded
2003
Market Cap
567.72M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
277.26K
High Today
$16.33
Low Today
$15.69
Open Price
$16.03
Volume
179.07K
52 Week High
$17.14
52 Week Low
$4.16

MRNS Earnings

-$0.60
-$0.40
-$0.20
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 15, After Hours

You May Also Like

LAUR
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure